NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.50
  • Forecasted Upside: 1.03 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$21.28
▲ +0.19 (0.90%)

This chart shows the closing price for AMPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amphastar Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMPH

Analyst Price Target is $21.50
▲ +1.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $21.50, with a high forecast of $23.00 and a low forecast of $20.00. The average price target represents a 1.03% upside from the last price of $21.28.

This chart shows the closing price for AMPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Amphastar Pharmaceuticals. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/20/2021Northland SecuritiesReiterated RatingBuy$23.00Medium
3/17/2021Wells Fargo & CompanyLower Price TargetEqual Weight$21.00 ➝ $20.00Medium
1/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$21.00High
10/5/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$24.00High
8/7/2020Northland SecuritiesReiterated RatingHold$23.00High
7/9/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform$23.00High
6/10/2020Needham & Company LLCReiterated RatingHoldMedium
6/8/2020Northland SecuritiesReiterated RatingBuy$23.00Medium
5/14/2020Northland SecuritiesReiterated RatingBuy$23.00High
5/11/2020BMO Capital MarketsBoost Price TargetMarket Perform$20.00 ➝ $21.00High
5/7/2020Northland SecuritiesReiterated RatingBuyMedium
5/1/2020Northland SecuritiesInitiated CoverageOutperform$23.00Low
4/27/2020Needham & Company LLCReiterated RatingHoldLow
1/29/2020Needham & Company LLCReiterated RatingHoldHigh
6/6/2019Wells Fargo & CompanySet Price TargetBuy$29.00Low
5/10/2019Wells Fargo & CompanyReiterated RatingBuyHigh
3/13/2019Needham & Company LLCDowngradeBuy ➝ Hold$22.20High
3/13/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$24.00 ➝ $23.00High
11/14/2018Jefferies Financial GroupReiterated RatingBuy$26.00Medium
11/9/2018Needham & Company LLCSet Price TargetBuy$25.00N/A
11/9/2018Wells Fargo & CompanyReiterated RatingBuyHigh
8/10/2018Needham & Company LLCLower Price TargetBuy$24.00 ➝ $22.00Low
3/21/2018Wells Fargo & CompanyReiterated RatingBuyMedium
3/13/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$17.00 ➝ $19.00High
3/13/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $24.00High
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$26.00Medium
12/1/2017Needham & Company LLCBoost Price TargetBuy$20.00 ➝ $23.00Medium
11/10/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 ➝ $17.00N/A
11/9/2017Raymond JamesDowngradeOutperform ➝ Market Perform$18.00N/A
10/29/2017Jefferies Financial GroupSet Price TargetBuy$19.00N/A
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00N/A
9/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00Medium
9/17/2017Piper Jaffray CompaniesReiterated RatingBuy$19.00Low
8/11/2017Jefferies Financial GroupReiterated RatingBuy$20.00 ➝ $19.00Low
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$19.00Medium
7/31/2017BMO Capital MarketsReiterated RatingHold$16.00Low
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$20.00Low
7/22/2017Wells Fargo & CompanyReiterated RatingBuyMedium
5/10/2017Jefferies Financial GroupLower Price TargetBuy$21.00 ➝ $20.00Medium
4/20/2017Jefferies Financial GroupSet Price TargetBuy$21.00Low
3/14/2017Jefferies Financial GroupSet Price TargetBuy$21.00High
3/14/2017Raymond JamesDowngradeStrong-Buy ➝ Outperform$21.00 ➝ $18.00High
3/14/2017Piper Jaffray CompaniesLower Price TargetOverweight$22.00 ➝ $20.00High
3/14/2017BMO Capital MarketsLower Price TargetMarket Perform$18.00 ➝ $16.00High
3/14/2017Needham & Company LLCLower Price TargetBuy$20.00 ➝ $18.00High
12/21/2016Wells Fargo & CompanyReiterated RatingOutperform$22.00 ➝ $29.00N/A
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/10/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Read More

Today's Range

Now: $21.28
Low: $21.00
High: $21.30

50 Day Range

MA: $19.82
Low: $18.45
High: $21.30

52 Week Range

Now: $21.28
Low: $16.91
High: $21.70

Volume

129,162 shs

Average Volume

192,553 shs

Market Capitalization

$1.02 billion

P/E Ratio

29.56

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Amphastar Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Amphastar Pharmaceuticals in the last twelve months: Northland Securities, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for AMPH.

What is the current price target for Amphastar Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Amphastar Pharmaceuticals in the last year. Their average twelve-month price target is $21.50, suggesting a possible upside of 1.0%. Northland Securities has the highest price target set, predicting AMPH will reach $23.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $20.00 for Amphastar Pharmaceuticals in the next year.
View the latest price targets for AMPH.

What is the current consensus analyst rating for Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMPH will outperform the market and that investors should add to their positions of Amphastar Pharmaceuticals.
View the latest ratings for AMPH.

What other companies compete with Amphastar Pharmaceuticals?

How do I contact Amphastar Pharmaceuticals' investor relations team?

Amphastar Pharmaceuticals' physical mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company's listed phone number is (909) 980-9484 and its investor relations email address is [email protected] The official website for Amphastar Pharmaceuticals is www.amphastar.com.